Table 1.
Baseline characteristics of patients received NA therapy (VR versus non-VR).
| Variables | VR group (n = 744) | non-VR group (n = 521) |
|---|---|---|
| Age, y | 55.4 (18-75) | 56.5 (18-75) |
| Sex | ||
| Male | 657 (88.3) | 466 (89.4) |
| Female | 87 (11.7) | 55 (10.6) |
| Cirrhosis | ||
| Yes | 475 (63.8) | 343 (65.8) |
| No | 269 (36.1) | 178 (34.2) |
| Ascites | ||
| Yes | 35 (4.7) | 28 (5.4) |
| No | 709 (95.3) | 493 (94.6) |
| Splenomegaly | ||
| Yes | 591 (79.4) | 410 (78.7) |
| No | 153 (20.6) | 111 (21.3) |
| ICGR 15 | ||
| ≤10% | 622 (83.6) | 451 (86.6) |
| >10% | 122 (16.4) | 70 (13.4) |
| Tumor capsule | ||
| Yes | 223 (30.0) | 140 (26.9) |
| No | 521 (70.0) | 381 (73.1) |
| Up-to-seven criteria | ||
| Within | 544 (73.1) | 396 (76.0) |
| Beyond | 200 (26.9) | 125 (24.0) |
| AFP, ug/L | ||
| ≤20 | 220 (29.6) | 134 (25.7) |
| >20 | 524 (70.4) | 387 (74.3) |
| GGT, u/L | 210 (45.6-989.3) | 242 (40.6-896.8) |
| AST, u/L | 36 (10-116) | 35 (10-123) |
| ALT, u/L | 24 (10-120) | 21 (10-120) |
| Albumin, g/L | 37 (33-47) | 36 (34-49) |
| TBIL, umol/L | 12.4 (5.2-25.0) | 11.3 (3.8-26.3) |
| PT, sec | 9.3 (7.4-15.4) | 8.7 (6.8-17.5) |
| WBC, 109/L | 6.1 (4-10) | 5.4 (4-10.0) |
| HB, g/L | 13.4 (11.3-14.6) | 12.8 (11.7-14.7) |
| Platelet count, 109/L | 115 (90-450) | 112 (90-456) |
| Treatment cycles, n | 3 (1-6) | 3 (1-6) |
| Other treatment after TACE | ||
| None | 494 (66.4) | 370 (71.0) |
| Sorafenib | 174 (23.4) | 104 (20.0) |
| Radical therapy | 57 (7.7) | 35 (6.7) |
| Radiotherapy or chemotherapy | 19 (2.5) | 12 (2.3) |
Data are presented as median (range) or number (percentage).
AFP, alpha fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; HB, hemoglobin; ICGR, indocyanine green retention rate; NA, nucelos(t)ide analogue; PT, prothrombin time; TACE, transarterial chemoembolization; TBIL, total bilirubin; VR, virological response; WBC, white blood cells.